170th ACNFP Meeting

Executive Summary

• Dried Miracle Berry RP1351 and Krill Protein Hydrolysate RP1290 - The final CADs for these two novel food applications which were reviewed intersessionally were agreed with minor edits. These will proceed on to the publication process.
• THC statement (reserved business) - the Committee reviewed a draft joint statement of the ACNFP and COT on Δ9 THC as a contaminant of hemp derived food. The statement was agreed subject to minor amendments for clearance by Chair’s action.
• CBD RP 340 (reserved business) - The Committee reviewed a draft Committee Advice Document for highly purified isolated CBD for the second time.  Additional data provided by the applicant on genotoxicity of the novel food to support the safety of the novel food was reviewed. More information was requested from the applicant regarding solvent residues. Subject to their response, the Committee Advice Document will be revised and cleared by Chair’s action.
• CBD RP176 (reserved business) - the Committee reviewed a CBD application for 97.5% purity CBD isolate. The Committee recommended discussing the specification with the applicant. The Committee Advice Document will be updated based on the feedback and cleared by Chair’s action.
• CBD RP294 (reserved business) - the Committee reviewed a CBD application for 97% purity CBD isolate. The Committee recommended discussing the specification with the applicant. The Committee Advice Document will be updated based on the feedback and cleared by Chair’s action.
• Open session on Cell Cultivated Products - the Committee discussed the uncertainties associated with the key hazards for this group of applications and how they will impact safety assessment of these applications. The session was observed by 25 external observers. The points raised will inform the key questions to be considered by the FSA CCP sandbox and ACNFP CCP Subgroup.
• Fermotein RP1215 - The Committee reviewed this novel food application for the first time. The discussion identified various areas that required further information to complete the assessment with one of the key area being the bioinformatics analysis for this novel food. The Secretariat was advised to seek further information from the applicant. The CAD will be updated in light of the discussions to be reviewed at another meeting with the applicant’s response.
• Solein RP1326 – The Committee reviewed this novel food application for the first time. The discussion identified various areas that required further information to complete the assessment with one of the key area being the bioinformatics analysis for this novel food. The Secretariat was advised to seek further information from the applicant. The CAD will be updated in light of the discussions to be reviewed at another meeting with the response from the applicant.
• MS11 × RF3 × MON 88302 BRASSICA NAPUS (OILSEED RAPE), RP2029- The Committee reviewed this GM application that had previously been reviewed by the PGT Subgroup. The final CAD was agreed with minor suggested edits. This will now proceed on to the publication process.
• Bt11 × MIR162 × MIR604 × MON 89034 × 5307 × GA21 MAIZE, RP2044 - The Committee reviewed this GM application that had previously been reviewed by the PGT Subgroup. The final CAD was agreed with minor suggested edits. This will now proceed on to the publication process.
• EPA+DHA BRASSICA NAPUS L. (OILSEED RAPE), RP2065 - The Committee these three GM applications that had previously been reviewed by the PGT Subgroup. The final CADs were agreed with minor suggested edits. This will now proceed on to the publication process.

Agenda

170th Meeting of the ACNFP 5th & 6th February 2025 Agenda

Minutes

Minutes of the 170th Meeting held on the 5th and 6th of February 2025

Meeting Papers

CCP Open Session Paper

Fermotein®

Solein